[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100551671":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":24,"locations":29,"responsibleParty":47,"collaborators":10,"id":51,"slug":52,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":53,"sex":58,"minAge":10,"maxAge":10,"enrollmentInfo":59,"targetDuration":62,"studyType":63,"phases":10,"briefSummary":64,"conditions":65,"keywords":67,"overallStatus":31,"whyStopped":10,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":78},{"fullName":5,"class":6},"Pediatric Clinical Research Platform","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Immunocompromised patients",null,"Priority will be given to patients with the following disease compromising their immune system:\n\n* Solid organ recipients\n* Hematopoietic stem cell transplant recipients\n* HIV\n* Dysimmune disorders\n\n  * Inflammatory bowel disease\n  * Rheumatologic disease\n  * Neuro-immunological disease\n  * Nephrotic syndrome\n* Primary immunodeficiency disorder\n* Pneumological disease requiring immunosuppression (e.g. bronchiolitis obliterans)\n* Oncological disease",[13],"Other: Collection of data in a registry",[15],{"type":6,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"Collection of data in a registry","The aim of this observational project is to document the immunogenicity and reactogenicity of vaccines given to immunocompromised patients and collect it in a registry.",[9],[20],{"name":21,"affiliation":22,"role":23},"Laure F Pittet, MD-PhD","University Hospitals of Geneva","PRINCIPAL_INVESTIGATOR",[25],{"name":21,"role":26,"phone":27,"phoneExt":10,"email":28},"CONTACT","0223725481","laure.pittet@hcuge.ch",[30],{"facility":22,"status":31,"city":32,"state":10,"zip":33,"country":34,"countryCode":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"RECRUITING","Geneva","1211","Switzerland","CH",{"type":37,"coordinates":38},"Point",[39,40],6.14569,46.20222,{"lat":40,"lon":39},[43,46],{"name":21,"role":26,"phone":44,"phoneExt":10,"email":45},"0795538277","laure.pittet@hug.ch",{"name":21,"role":23,"phone":10,"phoneExt":10,"email":10},{"type":48,"investigatorFullName":49,"investigatorTitle":50,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"SPONSOR_INVESTIGATOR","Laure Pittet, MD-PhD","Clinical Scientist","100551671","registry-of-vaccine-responses-in-immune-compromised-patients-100551671",false,"NCT06463119","Registry of Vaccine Responses in Immune Compromised Patients","REVAPI","Inclusion Criteria:\n\n1. Immune compromised patient or patient who will soon be immunocompromised\n2. Informed consent as documented by signature\n\nExclusion Criteria:\n\n1. Individual\u002Fparental inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, known\u002Fsuspected non-compliance, substance abuse, etc.\n2. Plan to move out of the country or have prolong absence in the next 2 months","ALL",{"count":60,"type":61},300,"ESTIMATED","5 Years","OBSERVATIONAL","The aim of this project is to monitor, guide and document vaccination, vaccine responses, persistence of protection, vaccine efficacy and safety in immune compromised patients at various moment of their disease: right after the diagnosis, before the introduction of the immunosuppressive treatment, once the individual is under immunosuppressive treatment, or once immunosuppression is over.",[66],"Immunosuppression",[68],"Vaccine","2024-11-06",{"date":71,"type":72},"2024-11-07","ACTUAL",{"date":74,"type":72},"2024-09-24",{"date":76,"type":61},"2029-04",{"name":49,"class":6},1]